Skip to main content

Ypsomed Holding AG (YPHDF)

New York Stock Exchange Healthcare Medical - Instruments & SuppliesView data quality →
50.5Fair

ValueMarkers Composite Index

Top 34%#29,339 of 44,707

DCF data not available

Piotroski
7/9
Strong
Beneish
-2.23
Low Risk
Altman
5.93
Safe
DCF Value
-
N/A
ROIC
13.7%
Adequate
P/E
20.0
Fair
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Ypsomed Holding AG (YPHDF) — VMCI valuation read

The headline on Ypsomed Holding AG (YPHDF) is a 51/100 VMCI score, set against a Healthcare sector median of 50. That 1-point above-median read reflects the five-pillar weighting and, for a mid-cap name, suggests a relative-value tailwind is in the data.

YPHDF insider activity report: 0 buys, 0 sells filed via Form 4 over the past 30 days. The next datable items are the 10-Q schedule and any 8-K-triggering events; both feed the VMCI Integrity pillar more than the price tape.

**Investor frame.** YPHDF trades at 17.0x earnings, 6% below the Healthcare median of 18.0x sets the value side. ROIC of 15.0% sits 5.0pp above the Healthcare median (10.0%) sets the quality side. Net debt to EBITDA of 1.6x is the rate-sensitivity line to watch sets the risk side, the three lines a value buyer reads first on YPHDF.

YPHDF fell 1.3% over the trailing 7 days, with a -23.0% read on a 30-day basis.

Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for pharmaceutical and biotechnology companies. The company operates in two segments, Ypsomed Delivery Systems and Ypsomed Diabetes Care. The Ypsomed Delivery Systems segment provides various injection systems, such as pen injectors, auto injectors, patch injectors, and wearable injectors, as well as other smart devices. This segment offers its products under the YDS brand. The Ypsomed Diabetes Care segment sells and trades in insulin pumps, infusion sets, pen needles, blood glucose monitoring systems, accessories, and other day-to-day items for diabetics. This segment offers its products under the mylife brand name. The company offers precision turned parts; and contract manufacturing and other services. It markets its products through biotechnology and pharmaceutical partners, as well as through its own distribution network and independent distributors. It operates in Switzerland, Europe, North America, and internationally. Ypsomed Holding AG was founded in 1984 and is headquartered in Burgdorf, Switzerland.

CEO: Simon Michel2,600 employeesCHwww.ypsomed.com

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in YPHDF’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.